Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > RUN FOR THE HILLS! IT'S KALYTERA TIME AGAIN.

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Jun 15, 2021 4:14pm

230 Views

Post# 33390153

RUN FOR THE HILLS! IT'S KALYTERA TIME AGAIN.

WHAT DID YOU THINK WAS GOING TO HAPPEN.? BE HAPPY THAT THE PRICE DIDN'T FALL TO .01

BOB AND THE BOYS ARE FINDING IT HARDER AND HARDER TO GET NEW UNINFORMED INVESTORS TO JOIN KALYTERA. CHANGE THE NAME AND HOPE THAT NO ONE NOTICES WHAT A DUD THIS IS.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec